Pharmacopeia Commission Signed MoU with
Industry Bodies
Ø IPC Signs MoUs with the Pharmaceuticals
& Medical Devices Bureau of India and National Institute of Pharmaceuticals
Education & Research, Hajipur, to Promote Drug Quality, Research, and Patient
Safety
Ø IPC–PMBI Partnership to Transform Quality
Assurance, Strengthen Pharmacovigilance, and Institutionalize Rational Drug Use
Across Jan Aushadhi Kendras Nationwide
Ø IPC–NIPER Hajipur MoU to Advance Pharmaceutical
Research, Strengthen Pharmacopoeial Standards, and Enhance
Safety of Biologics and Emerging Therapies
Key Highlights
1. IPC–PMBI Partnership for Drug Quality
and Patient Safety
·
Indian Pharmacopoeia Commission signed an MoU with Pharmaceuticals and Medical
Devices Bureau of India to strengthen quality assurance for medicines sold through
Pradhan Mantri Bhartiya Janaushadhi Kendras (PMBJKs).
·
Key focus areas include:
o Random batch testing of Jan Aushadhi medicines
by IPC
o Promotion of the National Formulary
of India (NFI) for rational drug use
o Strengthening pharmacovigilance
and adverse drug reaction (ADR) reporting
o Display of Pharmacovigilance Programme
of India (PvPI) QR code and helpline across Jan Aushadhi Kendras
o Joint training and awareness programs
for pharmacists and stakeholders
2. IPC–NIPER Hajipur Collaboration for
Advanced Research
·
IPC also signed an MoU with National Institute of Pharmaceutical Education
and Research Hajipur to advance pharmaceutical science and safety standards.
·
Collaboration will support:
o Research on impurity profiling,
including nitrosamines
o Development of standards for biologics,
biosimilars, cell and gene therapies
o Analytical methods, quality control protocols
and reference standards for the Indian Pharmacopoeia
o Academic exchange, internships, fellowships
and joint scientific publications
3. Capacity Building and Institutional
Strengthening
·
Both MoUs include:
o Training programmes, workshops and conferences
o Faculty exchange initiatives
o Shared use of advanced analytical instrumentation
facilities
o Collaborative research and capacity-building
efforts
Strategic Significance
·
Strengthens drug quality assurance, rational medicine use,
and patient safety nationwide.
·
Supports innovation in pharmacopoeial
science and emerging therapies.
Overall Message
The twin MoUs mark a significant step
toward stronger medicine quality oversight, deeper pharmaceutical research, and
enhanced patient safety, while supporting India’s broader public health and
pharma innovation goals.
[ABS News Service/25.04.2026]
Under the visionary leadership of Hon’ble
Prime Minister Shri Narendra Modi, India continues to strengthen its commitment
to ensuring access to quality healthcare and advancing pharmaceutical excellence
through strategic institutional collaborations. In line with this vision, the Indian
Pharmacopoeia Commission (IPC), Ministry of Health and Family Welfare, Government
of India, signed two significant Memoranda of Understanding (MoUs) with the Pharmaceuticals
& Medical Devices Bureau of India (PMBI), Department of Pharmaceuticals, Ministry
of Chemicals and Fertilizers, Government of India, and the National Institute of
Pharmaceutical Education and Research (NIPER), Hajipur, Bihar, an autonomous institution
under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers,
Government of India.
The MoU between IPC and PMBI aims to enhance
the quality assurance framework for medicines made available through Pradhan Mantri
Bhartiya Janaushadhi Kendras (PMBJKs). Under this collaboration, PMBI may submit
randomly selected batches of Jan Aushadhi medicines to IPC for quality testing.
The partnership will further promote the use of the National Formulary of India
(NFI) across Pradhan Mantri Bhartiya Janaushadhi Kendras (PMBJKs) to ensure rational
use of medicines. It also seeks to strengthen pharmacovigilance activities by displaying
the Pharmacovigilance Programme of India (PvPI) QR code
and toll-free helpline number (1800-180-3024) at PMBJKs across the country, thereby
encouraging adverse drug reaction (ADR) reporting and improving patient safety.
In addition, IPC and PMBI will jointly organize sensitization, awareness, and training
programmes for pharmacists and stakeholders on rational use of medicines, pharmacovigilance,
ADR reporting tools, and the role of pharmacists in safeguarding public health.
The MoU signed between IPC and NIPER,
Hajipur focuses on collaborative research, academic exchange, and capacity building
in the area of pharmaceutical science and healthcare products. NIPER Hajipur, an
Institute of National Importance, possesses advanced expertise in pharmaceutical
analysis, biologics, and clinical research, making it a valuable partner in strengthening
pharmacopoeial science and patient safety. This collaboration
will include joint research programmes on impurity profiling, including genotoxic
impurities such as nitrosamines, and their correlation with adverse drug reaction
data to establish evidence-based pharmacopoeial limits.
It will also focus on the development of analytical methods, quality control protocols,
and reference standards for biologics, biosimilars, and emerging cell and gene therapy
products for inclusion in the Indian Pharmacopoeia.
Both institutions will also collaborate
in organizing training programmes, workshops, seminars, and conferences, along with
faculty exchange initiatives and sharing of advanced analytical instrumentation
facilities. Internship and fellowship opportunities for pharmacy graduates and postgraduates,
as well as joint publication of research papers, training manuals, and educational
materials, will further strengthen scientific engagement and institutional capacity
building.
These MoUs reflect IPC’s continued efforts
to strengthen India’s healthcare ecosystem by promoting quality assurance, patient
safety, rational use of medicines, and innovation in pharmaceutical standards. Such
collaborations will further reinforce India’s position as a global leader in pharmaceutical
quality, regulatory excellence, and public health advancement.